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Background: Comorbid anxiety symptoms,in patients with a primary anxiety disorder or a mood disorder, leads to
poor patient outcomes and burdens the healthcare system. This pilot study evaluated the feasibility of
extended-release quetiapine fumarate (quetiapine XR) for the treatment of patients with either a primary anxiety
disorder or a mood disorder with comorbid anxiety symptoms compared to a placebo, as an adjunct to
antidepressant therapy.
Methods: Thirty-nine patients with a diagnosis of a primary anxiety disorder or a mood disorder with comorbid
anxiety symptoms were enrolled in this study. Patients with a stable dose of antidepressant therapy were
randomized according to a 2:1 probability of receiving either quetiapine XR or a placebo adjunctive treatment for
8 weeks. The efficacy was assessed by the Hamilton Anxiety Rating Scale (HAM-A) and the Clinical Global
Impression of severity (CGI-S) score at baseline, week 1, 4, and 8.
Results: A total of 35 patients were included in this intention-to treat (ITT) population for the efficacy analysis
(quetiapine XR: 22 patients; placebo: 13 patients). At week 4, statistically significant differences were observed on
both the HAM-A score (p = 0.003) and the CGI-S score (p = 0.025), favouring the quetiapine XR (−13.00 ± 4.14)
compared to placebo (−6.63 ± 5.42). However, no statistically significant difference was observed between the two
groups with regard to changes from the baseline to week 8 on the HAM-A score (p = 0.332) or the CGI-S score
(p = 0.833).
Conclusions: Augmentation of antidepressant treatment with quetiapine XR did not result in clinical improvement
according to the outcome measure of anxiety using the HAM-A and CGI-S scores at week 8, among the patients
with either a primary anxiety disorder or a mood disorder with comorbid anxiety symptoms. However, treatment
with quetiapine XR as an adjunct to antidepressant therapy appeared to provide a short-term benefit at 4 weeks.
Further study is needed with a larger sample size, randomized controlled design and control of the
dosage prescribed.
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Anxiety disorders can manifest as a primary disorder or as
a comorbid symptom associated with other psychiatric
disorders such as a major depressive disorder, bipolar dis-
order, schizophrenia, or a substance abuse disorder. Major
depressive disorder (MDD) with comorbid anxiety is
highly prevalent: ~85% of adults with major depression
also exhibit significant anxiety symptoms [1]. Comorbid
anxiety leads to more severe symptoms, decreased psy-
chosocial functioning, a higher risk of suicide and a more
chronic course, compared to a major depressive disorder
alone [2,3]; in addition, it is associated with poorer and
slower treatment response [1,4]. The treatment options
for primary anxiety and comorbid anxiety symptoms in-
clude: selective serotonin reuptake inhibitors (SSRI),
serotonin-norepinephrine reuptake inhibitors (SNRI), tri-
cyclic antidepressants and other antidepressants. However,
not all patients equally benefit from the anxiolytic effects
of antidepressants.
Treatment strategies for patients with anxiety disorders
and comorbid anxiety symptoms that have not responded
to therapy with an antidepressant include: changing the
antidepressant monotherapy, augmentation with another
agent or combination therapy with another antidepressant
agent [5]. Although augmentation or combination therapy
is commonly used in clinical practice, evidence supporting
these strategies is limited [6,7]. The benzodiazepines are
frequently used to treat sleep and anxiety in addition to
SSRI therapy for a major depressive disorder with comor-
bid anxiety; however, cognitive impairment and concerns
with regard to potential abuse and/or dependency with
these agents has limited their use. In clinical practice, the
atypical antipsychotics are commonly used as augmenta-
tion therapy in patients presenting with a mood disorder
(typically a major depressive disorder) with comorbid anx-
iety symptoms [8-11].
Support for investigation of atypical antipsychotics in
patients presenting with a mood disorder and comorbid
anxiety is based in part on preclinical studies suggesting
that several atypical antipsychotics are potent 5-HT2A
antagonists at low doses [12-14] and may facilitate the ac-
tion of serotonin at the 5-HT1A receptor, thereby aug-
menting the efficacy of antidepressants [15]. In addition,
certain atypical antipsychotics have other pharmacologic
properties that may contribute to antidepressant effects
including: α2 antagonism (risperidone), 5-HT1A agonism
(aripiprazole and ziprasidone) and monoamine reuptake
blockade (ziprasidone). Furthermore, there is some evi-
dence that atypical antipsychotics are effective in the treat-
ment of anxiety symptoms, suggesting their possible
clinical utility for major depression and comorbid anxiety
[16-19].
Quetiapine is known as an atypical antipsychotic with a
moderate affinity for 5-HT2A serotonergic, α1-adrenergic,muscarinic and histaminergic receptors, a minor affinity
for dopamine D2 and 5-HT1A receptors, and a low affin-
ity for 5-HT2C, α2-adrenergic and D1 receptors [20].
While atypical antipsychotics have been successfully used
for the treatment of mood disorders with comorbid anx-
iety, comprehensive data on the clinical efficacy of adjunct-
ive antidepressant therapy with quetiapine for patients
with a primary anxiety disorder or a mood disorder with
comorbid anxiety has not been collected. This pilot study
evaluated the feasibility of a randomized, placebo-
controlled study design for testing the safety and efficacy of
extended-release quetiapine fumarate (quetiapine XR) as
adjunctive therapy added to antidepressants for the treat-
ment of patients presenting with a primary anxiety dis-
order or a mood disorder with comorbid anxiety.
Methods
The study was conducted using a randomized double-
blind placebo-controlled design. The study was carried
out at a single site and was approved by the institutional
review board at the Chang Gung Memorial Hospital,
Keelung, Taiwan. Written informed consent was obtained
from all subjects before participation. The investigation
was recorded in the clinical registry as NCT00912535.
Patient population
For the present study, patients were randomized accord-
ing to a 2:1 probability of receiving either quetiapine XR
or a placebo for 8 weeks in order to minimize exposure to
antidepressant monotherapy (placebo-controlled group).
For inclusion in the study the patients fulfilled all of the
following criteria: (1) provision of written informed con-
sent, (2) diagnosis of a primary anxiety disorder or a mood
disorder with comorbid anxiety symptoms by the Diag-
nostic and Statistical Manual of Mental Disorders-Fourth
Edition (DSM-IV) [21], (3) a 14-item Hamilton Anxiety
Scale score (HAM-A) ≥14 [22], (4) the subject had
received a single antidepressant at a therapeutic dose for
at least 6 weeks, (5) male or female gender 18–65 years of
age, (6) female patients of childbearing potential were
using a reliable method of contraception and had a nega-
tive urine human chorionic gonadotropin (HCG) test at
enrolment, (7) and were able to understand and comply
with the requirements of the study and sign the informed
consent.
Any of the following was regarded as a criterion for ex-
clusion from the study: (1) pregnancy or lactation, (2) any
DSM-IV Axis I disorder not defined in the inclusion cri-
teria, (3) receiving any antipsychotic 7 days prior to enter-
ing the study, (4) patients who, in the opinion of the
investigator, posed an imminent risk of suicide or a danger
to self or others, (5) administration of a depot anti-
psychotic injection within one dosing interval (for the
depot) before randomization, (6) substance dependence or
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for caffeine or nicotine), as defined by DSM-IV criteria, (7)
unstable or inadequately treated medical illness (e.g. con-
gestive heart failure, angina pectoris, hypertension) as
judged by the investigator, (8) and/or previous enrolment
or randomization of treatment in the present study.
Randomization
Subjects were strictly randomized sequentially. The
randomization code was generated according to a
randomization table, was sealed in envelopes and subse-
quently distributed to the study site prior to study initi-
ation (Additional file 1).
Blinding
Patients received one of two treatment packages according
to a treatment allocated randomization number. Quetia-
pine XR and its matching placebo were indistinguishable
in terms of appearance, smell, taste and dose regimen.
Neither the investigators nor subjects knew whether the
treatment package received by the patients was the study
drug or placebo. AstraZeneca Ltd provided the packages.Figure 1 For the present study, patients were randomized with a 2:1
(N= 13) for 8 weeks in order to minimize exposure to a single SSRI/SN
who used the study medication and had at least one follow-up evaluation
21 patients completed the study.Study medication
Quetiapine XR was given orally at a flexible dose of 50-
300 mg/day according to the judgment of the investigator,
for 8 weeks, as adjunct to the antidepressant the patient
was taking. The placebo was given orally, as adjunct to the
antidepressant the patient was taking. Patients already re-
ceiving hypnotics or anxiolytic benzodiazepines were per-
mitted to continue taking them at the same dose.
Efficacy evaluations
The primary end point was the mean change from base-
line to Week 8 according to the total score on the Hamil-
ton Anxiety Scale (HAM-A) [22]. Additional efficacy
evaluations included the change from baseline to all time
points on the Clinical Global Impression–severity of ill-
ness (CGI-S) score [23].
Safety and tolerability evaluations
Safety was evaluated from baseline to the end of the study
by comparing clinically significant changes. The following
parameters were used: (1) Abnormal Involuntary Move-
ment Scale [24], (2) Barnes-Akathisia Rating scale [25], (3)probability of receiving either quetiapine (N= 26), or placebo
RI alone (placebo-controlled group). A total of 35 eligible patients
were included in the intention-to treat (ITT) population. A total of
Table 1 Demographic and other baseline characteristics







Mean (S.D.) 42.32 (8.99) 48.57 (9.17)
Median 40.15 47.95
Height, cm 0.699
Mean (S.D.) 159.77 (5.70) 160.62 (6.91)
Median 158.50 160.00
Gender 0.832
Male 4 (18%) 2 (15%)
Female 18 (82%) 11 (85%)
HAM-A –
Mean (S.D.) 24.73 (4.45) 27.15 (3.95)
Median 24.00 28.00
ITT population Intention-to-treat population, HAM-A Hamilton Anxiety Scale.
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body weight, (6) vital signs, (7) and adverse events (AEs).
Statistical analyses
Data analysis and summary of safety and efficacy were
performed on the intention-to-treat (ITT) population; this
included patients that had taken at least one dose of the
study medication and had at least one evaluation for the
primary efficacy endpoint, regardless of their compliance
with the protocol. A last-observation-carried-forward
(LOCF) analysis was applied if data were unavailable at
the analysis time point. A two-sample t-test was used for
continuous variables and the chi-square test was applied
to all categorical variables. An analysis of covariance
(ANCOVA) was used to test superiority of the treatment
group over the placebo group for changes from baseline
according to the total scores on the HAM-A and the CGI-
S. All statistical tests were two-tailed, and the level of sig-
nificance was set at p < 0.05.
Results
Disposition of patients
The patient flow is shown in Figure 1. A total of 35 eligible
patients that received study medication and had at least
one follow-up evaluation were included in the intention-
to-treat (ITT) population (quetiapine XR: 22 patients; pla-
cebo: 13 patients). The antidepressants that were taken by
the patients included escitalopram, paroxetine, venlafax-
ine, duloxetine and mirtazapine. A total of 21 eligible
patients (quetiapine XR: 13 patients; placebo: 8 patients)
completed the study. Table 1 shows the demographic data
of the ITT population. All demographic data was compar-
able between the quetiapine XR group and the placebo
group with no statistically significant differences (p> 0.05).
At baseline, the total HAM-A score, among the ITT
population with LOCF, was 24.73± 4.45 and 27.15 ± 3.95
in quetiapine XR and placebo groups, respectively.
Throughout the study, the mean percent age of study drug
taken was 99.78 ± 18.74% in the quetiapine XR group, and
95.21 ± 10.61% in the placebo group. The mode and me-
dian dose of quetiapine XR was 50 mg/day, in this study.
Change from baseline to Week 8 on the total
HAM-A scores
At Week 8, the mean HAM-A score was 13.15 ± 5.30 and
18.13 ± 5.69 for quetiapine XR and placebo groups, re-
spectively; there was no statistically significant difference
observed between the two groups with regard to changes
from baseline to Week 8.In a subgroup analysis, there was
no statistically significant difference (p= 0.175) in the
HAM-A score between patients treated with quetiapine
XR (N=10) or placebo (N= 7) among the group with a
primary anxiety disorder. In addition, there was no signifi-
cant difference (p= 0.241)in this measure, in the patientstreated with quetiapine XR (N=12) or placebo (N= 6),
among the patients with a mood disorder and comorbid
anxiety symptoms. There was no significant difference in
the treatment response between these two groups.
At Week 4, however, there was an approximately two-
fold change from baseline to Week 4 in the HAM-A score
for patients receiving quetiapine XR (−13.00± 4.14) com-
pared to those receiving placebo (−6.63± 5.42) [p= 0.003]
(Figure 2).
Change from baseline to Week 8 in CGI-S scores
At Week 8, the mean CGI-S score was 3.50± 0.86 and
3.62± 0.51 for the quetiapine XR and placebo groups, re-
spectively; there was no statistically significant difference
observed between the two groups with regard to changes
from baseline to Week 8 on the CGI-S scores.
However, at Week 4, there was up to a 2.3-fold change
from baseline to Week 4 on the CGI-S score in patients
receiving quetiapine XR (−1.05± 0.95) compared to the
placebo group (−0.46± 0.52). A statistically significant dif-
ference was observed between the two groups in a change
from baseline to Week 4in the CGI-S score (p= 0.025)
(Figure 3).
Safety and tolerability
A total of 36 patients (quetiapine XR: 23 patients; placebo:
13 patients) were included in the drug safety analysis. The
rate of discontinuation due to adverse events was 17%
(N=4) in the quetiapine XR group and 23% (N=3) in the
placebo group. Throughout the treatment period, 27
patients reported 60 adverse events. There were 35 ad-
verse events reported by 17 patients in the quetiapine XR
group, and 25 adverse events reported by 10 patients in
the placebo group (Table 2). Furthermore, 17 patients in
Figure 2 During 8weeks of quetiapine XR augmentation to
antidepressant treatment among patients with a primary
anxiety disorder or a mood disorder with comorbid anxiety
symptoms, a statistically significant difference was observed
between the quetiapine XR group and placebo group at Week
4 compared to baseline on the total HAM-A scores (p = 0.003).
However, no statistically significant difference was observed
between the two groups at Week 8 compared to baseline on the
total HAM-A scores. HAM-A: Hamilton Anxiety Scale.
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group reported treatment-related adverse events. All treat-
ment related adverse events were considered to be “Mild”
or “Moderate” in severity by the investigator. None of the
patients in the quetiapine XR or placebo groups experi-
enced a serious adverse event during the treatment period.
The most common adverse events reported by patients
were: dry mouth, dizziness, somnolence, constipation and
sedation.Figure 3 During 8weeks of quetiapine XR augmentation to antidepre
or a mood disorder with comorbid anxiety symptoms, a statistically s
group and the placebo group at Week 4 compared to baseline on th
difference was observed between the two groupsat Week 8 compared to
of illness.At week 8, the changes in patient weight were
1.25± 1.87 and 2.44± 3.81 for the quetiapine XR and pla-
cebo groups, respectively. No statistically significant
changes were observed between the two groups from
baseline to week 4 and week 8. Throughout the study, one
patient in the quetiapine XR group had a weight gain ≥7%
at Week 8, while two patients in the placebo group had a
weight gain ≥7% at Week 1, Week 4 and Week 8. The
results of laboratory measurements, vital signs, physical
examinations, weight change and body mass index were
clinically comparable in comparisons between the two
groups. Throughout the treatment period, no effect on the
AIMS global severity scores was observed in the quetia-
pine XR or placebo groups. Moreover, there were no sta-
tistically significant differences between the two groups
according to the BARS and SAS rating scales.
Discussion
The primary outcome measures (HAM-A and CGI-S)
assessed in this pilot study showed no significant differ-
ences between the quetiapine XR and placebo groups at
week 8. However, treatment with quetiapine XR as an ad-
junct to antidepressant therapy appeared to provide a
short-term benefit at 4 weeks in difficult-to-treat patients
with primary or comorbid anxiety despite on-going anti-
depressant treatment. These results should be considered
preliminary due to the limitation of a small sample size.
Based on a mean change in the HAMA of 9 in the quetia-
pine XR arm and 4 in the placebo arm (difference = 5)
and a deviation of 8 for both treatments, 35 patients in
the placebo arm and 75 patients in the quetiapine XR armssant treatment among patients with a primary anxiety disorder
ignificant difference was observed between the quetiapine XR
e CGI-S score (p= 0.025). However, no statistically significant
baseline on the CGI-S score. CGI-S: Clinical Global Impression–severity
Table 2 Summary of treatment-related events






Subjects with at least 1 related
adverse event
17 (47%) 10 (28%)
Eye disorders 0 (0%) 1 (3%)
Vision blurred 0 (0%) 1 (3%)
Gastrointestinal disorders 9 (25%) 4 (11%)
Constipation 3 (8%) 2 (6%)
Dry mouth 7 (19%) 2 (6%)
Nausea 1 (3%) 0 (0%)
Vomiting 1 (3%) 0 (0%)
Investigations 3 (8%) 4 (11%)
Blood pressure increased 0 (0%) 1 (3%)
Glycosylated haemoglobin increased 0 (0%) 1 (3%)
Weight increased 3 (8%) 3 (8%)
Metabolism and nutrition disorders 2 (6%) 2 (6%)
Increased appetite 2 (6%) 2 (6%)
Nervous system disorders 11 (31%) 5 (14%)
Dizziness 4 (11%) 1 (3%)
Headache 1 (3%) 1 (3%)
Memory impairment 0 (0%) 1 (3%)
Restless legs syndrome 0 (0%) 1 (3%)
Sedation 3 (8%) 1 (3%)
Somnolence 4 (11%) 1 (3%)
Tremor 1 (3%) 1 (3%)
Renal and urinary disorders 1 (3%) 1 (3%)
Dysuria 1 (3%) 1 (3%)
Reproductive system and breast disorders 0 (0%) 1 (3%)
Oligomenorrhoea 0 (0%) 1 (3%)
Skin and subcutaneous tissue disorders 0 (0%) 1 (3%)
Rash papular 0 (0%) 1 (3%)
Chen et al. BMC Psychiatry 2012, 12:162 Page 6 of 7
http://www.biomedcentral.com/1471-244X/12/162would be needed to have a power of 85% at a significance
level of 0.05.
A previous flexible-dose open-label pilot study, reported
by Katzman et al., found that adjunctive quetiapine XR
significantly reduced HAM-A scores at week 12 in
patients with treatment-resistant or non-remitted GAD
[27]. The results of our study showed a significant reduc-
tion in the HAM-A score at Week 8 with adjunctive que-
tiapine XR. However, no statistically significant difference
was observed between the treatment and placebo groups.
Placebo effects clearly played a significant role in the re-
duction of anxiety measured in this study. The failure to
find a significant difference on the primary efficacy meas-
ure at week 8 could in part be explained by the small sam-
ple size as well as the heterogeneous study group.
Although quetiapine monotherapy has been demonstratedto be effective, demonstrating quetiapine efficacy as ad-
junct therapy to antidepressant has proven difficult
[28,29]. The analyses on the subsets of patients with a pri-
mary anxiety disorder and those with a mood disorder
and comorbid anxiety symptoms revealed no significant
difference in the treatment response between these two
groups. However, these analyses lacked statistical power
due to the small sample sizes after stratification.
Quetiapine XR was generally safe and well-tolerated as
adjunctive treatment in patients with primary or comorbid
anxiety [30,31]. In this study, EPS-related AEs were not
observed with quetiapine XR during the study period. La-
boratory data revealed no clinically relevant changes in
glucose in the patients receiving quetiapine XR. At week
8, the changes in patient weight were 1.25± 1.87 and
2.44± 3.81 for quetiapine XR and placebo groups, respect-
ively. However, the benign side effect profile, noted in this
study, might have been due to the low dose used.
In addition to the above-mentioned limitations associated
with the small sample size, other limitations of the present
study include the following. It is difficult to clearly distin-
guish patients with a primary anxiety disorder from those
with a mood disorder and comorbid anxiety symptoms.
Therefore, the possibility of misclassification could not be
ruled out. Regarding dosing, the dose of quetaipine XR in
this study was relatively low, and the flexible dosing sched-
ule might have confounded the results. A similar study in
the future should consider a multiple arms design with dif-
ferent fixed doses to determine dose-dependent effects.
Conclusion
Augmentation of antidepressant treatment with quetia-
pine XR did not result in clinical improvement in the out-
come measures of anxiety using the HAM-A and CGI-S
scores at week 8 in patients with either a primary anxiety
disorder or a mood disorder with comorbid anxiety symp-
toms. However, treatment with quetiapine XR as an ad-
junct to antidepressant therapy appeared to provide a
short-term benefit at 4 weeks. The results of this pilot
study should be considered preliminary due to the limita-
tions of a small sample size and the dosing strategy. A
well-powered sample size and a multiple-arms design with
different fixed doses to determine dose-dependent effects
should be considered for future studies.
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